127 related articles for article (PubMed ID: 37274049)
1. Bladder metastasis from epidermal growth factor receptor mutant lung cancer: A case report.
Jin CB; Yang L
World J Clin Cases; 2023 May; 11(14):3356-3361. PubMed ID: 37274049
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.
Joo JW; Hong MH; Shim HS
Lung Cancer; 2018 Jul; 121():12-17. PubMed ID: 29858020
[TBL] [Abstract][Full Text] [Related]
3. Choroidal metastasis from non-small-cell lung cancer responsive to Osimertinib: a case report : Efficacy of a third-generation epidermal growth factor tyrosine kinase inhibitor.
Mariachiara M; Celeste R; Federico F; Nicole B; Antonio C
Int Ophthalmol; 2018 Dec; 38(6):2669-2675. PubMed ID: 29071523
[TBL] [Abstract][Full Text] [Related]
4. Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.
Shastri M; Gupta P; Gupta N; Singh N; Bal A; Srinivasan R; Khosla D
Cytopathology; 2022 Nov; 33(6):732-737. PubMed ID: 35867808
[TBL] [Abstract][Full Text] [Related]
5. Squamous cell transformation and
Bruno R; Proietti A; Alì G; Puppo G; Ribechini A; Chella A; Fontanini G
Oncol Lett; 2017 Nov; 14(5):5947-5951. PubMed ID: 29113230
[TBL] [Abstract][Full Text] [Related]
6. Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report.
Uemura T; Oguri T; Okayama M; Furuta H; Kanemitsu Y; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Ito Y; Niimi A
Mol Clin Oncol; 2017 Apr; 6(4):525-528. PubMed ID: 28413660
[TBL] [Abstract][Full Text] [Related]
7. Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report.
Ma S; He Z; Fu H; Wang L; Wu X; Zhang Z; Wang Q
Transl Lung Cancer Res; 2020 Feb; 9(1):139-143. PubMed ID: 32206560
[TBL] [Abstract][Full Text] [Related]
8. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
9. T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review.
Kusaba Y; Takeda Y; Abe S; Tsukada A; Naka G
Medicine (Baltimore); 2022 Aug; 101(32):e29682. PubMed ID: 35960133
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
[TBL] [Abstract][Full Text] [Related]
11. Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Lin Q; Cai GP; Yang KY; Yang L; Chen CS; Li YP
BMC Cancer; 2016 Aug; 16():593. PubMed ID: 27488410
[TBL] [Abstract][Full Text] [Related]
12. Uterine metastasis of lung adenocarcinoma under molecular target therapy with epidermal growth factor receptor tyrosine kinase inhibitors: A case report and review of the literature.
Shibata M; Shizu M; Watanabe K; Takeda A
J Obstet Gynaecol Res; 2018 Feb; 44(2):352-358. PubMed ID: 29094453
[TBL] [Abstract][Full Text] [Related]
13. Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib.
Ren X; Cai X; Li J; Zhang X; Yu J; Song X; Zhang H; Song X
J Int Med Res; 2020 Jun; 48(6):300060520927918. PubMed ID: 32600081
[TBL] [Abstract][Full Text] [Related]
14. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
[TBL] [Abstract][Full Text] [Related]
15. A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report.
Zhou T; Xiong Q; Hong C; Wang Q; Wang W; Xu C; Cai J;
Medicine (Baltimore); 2022 Aug; 101(34):e30269. PubMed ID: 36042660
[TBL] [Abstract][Full Text] [Related]
16. An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.
Chowaniecova G; Berzinec P; Kosturiakova G; Plank L; Farkasova A; Sekeresova M; Juskanic D; Ondrus D
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):451-454. PubMed ID: 36036563
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
18. The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.
Huang YH; Hsu KH; Tseng JS; Chen KC; Hsu CH; Su KY; Chen JJW; Chen HW; Yu SL; Yang TY; Chang GC
Cancer Res Treat; 2018 Oct; 50(4):1294-1303. PubMed ID: 29334606
[TBL] [Abstract][Full Text] [Related]
19. Concomitant T790M mutation and small-cell lung cancer transformation after acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor.
Fujita K; Kim YH; Yoshizawa A; Mio T; Mishima M
Respirol Case Rep; 2017 Jan; 5(1):e00206. PubMed ID: 28031840
[TBL] [Abstract][Full Text] [Related]
20. Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance.
Xu S; Liu X; Liu R; Shi T; Li X; Zhong D; Wang Y; Chen G; Chen J
Thorac Cancer; 2017 Nov; 8(6):693-697. PubMed ID: 28786540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
